Taysha IPO Presentation Deck

Taysha Investment Highlights Multiple product candidates with anticipated near- term catalysts to enhance value Portfolio of 18 CNS gene therapy programs across 3 distinct franchises UT Southwestern Gene Therapy Program strategic alliance Validated capsid, manufacturing system and route of delivery Proven management team and investor syndicate Gene therapy for GM2-Gangliosidosis anticipated to enter clinical studies later this year Gene therapy for CLN1 received approval for IND; anticipated to dose first patient in 2021 Four INDS expected to be submitted by the end of 2021; along with several product candidates in IND-enabling studies Current pipeline of 18 AAV gene therapy programs with options to acquire an additional 4 programs Portfolio addressing over 500,000 patients (US+EU) across monogenic CNS diseases, including neurodegenerative diseases, neurodevelopmental disorders, and genetic epilepsies Led by Drs. Steven Gray and Berge Minassian; established to accelerate R&D, with integration of translational research, clinical development and GMP manufacturing Exclusive access to resources, expertise, and novel technology platforms for delivery and dosing of gene therapies Clinically and commercially proven AAV9 vector platform Highly scalable suspension HEK293 manufacturing process with excellent yield Intrathecal route of administration enables direct targeting to the CNS with validated biodistribution and safety Deep expertise in the development of gene therapies for rare diseases Key leadership team members and investors previously led the development and commercialization of Zolgensma", the first FDA-approved gene therapy for CNS disease 5

View entire presentation